Friedrich (Fritz) Scheiflinger (Evotec Gene Therapy (Orth, AT, Evotec GT))

Scheiflinger, Friedrich (Fritz) (Evotec 202004 EVP Head Gene Therapy before Shire/Takeda 201707 Head Global Research)

	Organisation	Evotec Gene Therapy (Orth, AT, Evotec GT)
	Former/major organisation	Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ)
	Today	Shire Ltd. (LSE: SHP, NASDAQ: SHPGY)
	Group	Takeda (Group)
	Product	gene therapy
	Product 2	drug discovery services

Novimmune S.A.. (7/18/17). "Press Release: Novimmune and Shire Sign License Agreement Deepening Bispecific Antibody Research Collaboration". Geneva.

Novimmune grants Shire a worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A

Novimmune a privately held, Swiss biopharmaceutical company focused on the discovery and development of innovative antibody-based medicines, and Shire, the biotech leader in Rare Diseases, today announced they have entered into an agreement, granting Shire exclusive worldwide rights to develop and commercialize an innovative, bi-specific antibody in pre-clinical development for the treatment of hemophilia A. Novimmune is creating and optimizing a fully human, bi-specific IgG antibody targeting FIXa and FX, designed to imitate the body’s natural mechanism of Factor VIII driven coagulation. Shire’s ultimate aim is to deliver a treatment that is highly efficacious with fewer side effects that improves upon the strong and long-term record of efficacy and safety that has been set by the class of clotting factor treatments.

“Novimmune is building on a collaboration initiated in 2015 with Shire to generate and evaluate Factor VIII mimetic, bispecific antibodies,” said Ed Holdener, Chairman and CEO of Novimmune. “We are delighted that our research efforts have produced several promising and potentially highly differentiated leads for improving coagulation in hemophilia A.”

Novimmune has been developing a platform for making fully human, bispecific antibodies and has several in house programs targeting tumor associated antigens and the immune system check point protein CD47.

“This novel program builds on our extensive monoclonal antibody (MAb) capabilities, as well as on our in-depth scientific expertise in hematology,” said Fritz Scheiflinger, Head of Global Research, Shire. “While further development and clinical trials are needed to fully evaluate this antibody, we are delighted by the potential we have seen in early discovery and the promise it may hold for hemophilia A patients.”

The specific terms of this deal were not disclosed.

About Novimmune

Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based medicines for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and runs a Clinical and Commercial Development Center in Basel. The company currently employs 130 people. More information is available on the company website at www.novimmune.com.

Contact:
Adrian Mills amills@novimmune.com +41 (0) 61 201 13 27

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. Shire strives to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Shire employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Media Relations
Elizabeth Kalina ekalina@shire.com +1 781 482 2713
Gwen Fisher gfisher@shire.com +1 781 482 9649

Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874